<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Martin-Sanchez E</submitter><funding>European Research Council</funding><pagination>111</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11237013</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(1)</volume><pubmed_abstract>Infection is the leading cause of death in multiple myeloma (MM). However, the cellular composition associated with immune dysfunction is not defined. We analyzed immune profiles in the peripheral blood of patients with MM (n = 28) and B-cell chronic lymphoproliferative disorders (n = 53) vs. health care practitioners (n = 96), using multidimensional and computational flow cytometry. MM patients displayed altered distribution of most cell types (41/56, 73%), particularly within the B-cell (17/17) and T-cell (20/30) compartments. Using COVID-19 as a case study, we compared the immune response to vaccination based on 64,304 data points generated from the analysis of 1099 longitudinal samples. MM patients showed limited B-cell expansion linked to lower anti-RBD and anti-S antibody titers afte</pubmed_abstract><journal>Blood cancer journal</journal><pubmed_title>Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19.</pubmed_title><pmcid>PMC11237013</pmcid><funding_grant_id>680200</funding_grant_id><pubmed_authors>Grande C</pubmed_authors><pubmed_authors>Olazabal I</pubmed_authors><pubmed_authors>Guerrero C</pubmed_authors><pubmed_authors>Maia C</pubmed_authors><pubmed_authors>Oiartzabal I</pubmed_authors><pubmed_authors>Perez-Persona E</pubmed_authors><pubmed_authors>Zherniakova A</pubmed_authors><pubmed_authors>Fortuno MA</pubmed_authors><pubmed_authors>Gomez C</pubmed_authors><pubmed_authors>San-Miguel JF</pubmed_authors><pubmed_authors>Rodriguez-Otero P</pubmed_authors><pubmed_authors>Zabaleta A</pubmed_authors><pubmed_authors>Prosper F</pubmed_authors><pubmed_authors>Asociación Vasco-Navarra de Hematología y Hemoterapia (ASOVASNA) cooperative group</pubmed_authors><pubmed_authors>Arguinano JM</pubmed_authors><pubmed_authors>Paiva B</pubmed_authors><pubmed_authors>San Miguel JF</pubmed_authors><pubmed_authors>Panizo C</pubmed_authors><pubmed_authors>Martin-Sanchez E</pubmed_authors><pubmed_authors>Tamariz-Amador LE</pubmed_authors><pubmed_authors>Manubens A</pubmed_authors><pubmed_authors>Alignani D</pubmed_authors><pubmed_authors>Blanco L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19.</name><description>Infection is the leading cause of death in multiple myeloma (MM). However, the cellular composition associated with immune dysfunction is not defined. We analyzed immune profiles in the peripheral blood of patients with MM (n = 28) and B-cell chronic lymphoproliferative disorders (n = 53) vs. health care practitioners (n = 96), using multidimensional and computational flow cytometry. MM patients displayed altered distribution of most cell types (41/56, 73%), particularly within the B-cell (17/17) and T-cell (20/30) compartments. Using COVID-19 as a case study, we compared the immune response to vaccination based on 64,304 data points generated from the analysis of 1099 longitudinal samples. MM patients showed limited B-cell expansion linked to lower anti-RBD and anti-S antibody titers afte</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jul</publication><modification>2025-04-05T15:49:07.709Z</modification><creation>2025-04-05T15:49:07.709Z</creation></dates><accession>S-EPMC11237013</accession><cross_references><pubmed>38987557</pubmed><doi>10.1038/s41408-024-01089-5</doi></cross_references></HashMap>